Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Bretisilocin · 1 trial · 1 indication
An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
| Arm | Type | Description |
|---|---|---|
| Group 1-Bretisilocin-Japanese | EXPERIMENTAL | Participants will receive bretisilocin intramuscular (IM) injection on day 1. |
| Group 1-Bretisilocin-Han Chinese | EXPERIMENTAL | Participants will receive bretisilocin intramuscular (IM) injection on day 1. |
| Group 1-Bretisilocin-Non-Asian | EXPERIMENTAL | Participants will receive bretisilocin intramuscular (IM) injection on day 1. |
| Name | Type | Description |
|---|---|---|
| Bretisilocin | DRUG | Intramuscular Injection |
Inclusion Criteria: * Group 1: Healthy adult Japanese male or female; • Japanese participants must be first-generation Japanese of full Japanese parentage residing outside of Japan for less than 5 years. * Group 2: Healthy adult Han Chinese male or female • Han Chinese participants must be fi...
Bretisilocin is an investigational small molecule being developed by AbbVie Inc. (ticker ABBV). It is in Phase 1 clinical development and has been studied as an intramuscular injection in healthy adult volunteers. Its specific therapeutic indications have not been publicly disclosed.
Bretisilocin is being developed by AbbVie Inc., which trades on the New York Stock Exchange under the ticker ABBV. AbbVie is the sponsor of the clinical program evaluating the drug.
Bretisilocin is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. One Phase 1 trial has been completed, and no active trials are currently listed for the program.
Bretisilocin has been evaluated in one completed Phase 1 trial, NCT07604558, titled a study to assess adverse events and how bretisilocin intramuscular injection moves through the body of healthy adult participants. The trial enrolled 26 healthy adult volunteers in the United States and used a controlled design.
Bretisilocin has been studied as an intramuscular injection. The completed Phase 1 trial, NCT07604558, assessed adverse events and how the intramuscular injection moves through the body of healthy adult participants. It is a small molecule in clinical development.